Research Update

Deltex Medical Group PLC
1 September 2004


                        Deltex Medical Group plc


Publication of study results on the use of CardioQ TM haemodynamic monitoring
system in patients undergoing colorectal surgery


UK, 1 September 2004:  Deltex Medical Group plc ('Deltex Medical' or the 
'Company'), the AIM listed haemodynamic monitoring company, today announces the
publication, in the European Journal of Anaesthesiology, of the results of a
National Health Service sponsored pilot study looking at the use of its 
CardioQ TM system in patients undergoing colorectal (bowel) surgery.

Anaesthetist Dr. Howard Wakeling and his surgical colleagues at Worthing
Hospital in West Sussex used the CardioQ TM to guide fluid administration during
surgery in order to alleviate the dehydration ('hypovolaemia') that affects
almost all patients undergoing moderate and major surgical procedures.
Hypovolaemia commonly causes post-surgical complications that can extend
hospital stay and slow recovery. In severe cases hypovolaemia can lead to death.

Dr. Wakeling and his colleagues reported that patients who were haemodynamically
optimised using the CardioQ TM system were able to go home on average two days
earlier than those managed traditionally and had fewer complications following
their surgery.  Based upon these findings the investigators embarked upon a
prospective, randomised trial of this approach to patient management. The
results of this randomised trial will be presented at the Annual Congress of the
Association of Anaesthetists of Great Britain and Ireland on 23 September 2004.

Chief Executive, Andy Hill, commented:  'These results further support findings
already widely reported in the clinical literature and add to the rapidly
growing belief within the medical community that haemodynamic optimisation
should be a standard of care for all patients undergoing moderate and major
surgical procedures.  Haemodynamic optimisation brings important benefits to
both patients and healthcare systems by reducing the length of time in hospital
and the complications associated with hypovolaemia. Using our technology offers
a significant opportunity to improve quality of care and realise significant
economic benefits.'


For further information, please contact:-

Deltex Medical Group plc                                           01243 774 837
Nigel Keen, Chairman              [e-mail]
Andy Hill, Chief Executive        [e-mail]
Ewan Phillips, Finance Director   [e-mail]

Financial Dynamics
David Yates                       [e-mail]               0207 831 3113
Lucy Briggs                       [e-mail]



Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


•         validated the results of the Monitor against known standards for
          measuring cardiac output, demonstrating that the technology works

•         proved that the CardioQ works in a wide range of surgical procedures

•         demonstrated that the Company's technology provides significant health
          and economic benefits by helping to reduce post-operative 
          complications and length of hospital stays by an average of 30 to 40 
          per cent for a wide range of patients.



                      This information is provided by RNS
            The company news service from the London Stock Exchange